Developer docs
API playgroundTry for free, no card

Search company profiles

NovaLead Pharma

Full company profile

uuid000bo94

Namestring
NovaLead Pharma
Legal namestring
NovaLead Pharma Pvt. Ltd.
Company typeenum
Private
Founded yearstring
-
Descriptiontext

NovaLead Pharma is a Pune, India-headquartered drug discovery research company that applies its proprietary Reverse Virtual High Throughput Screening (RVHTS) platform to repurpose already-approved generic drugs toward new therapeutic indications. The platform blends structure-guided and ligand-based drug design and screening, runs millions of molecular simulations on a multi-core parallel processing cluster, and is supported by a curated drug-disease-target knowledgebase that maps FDA-approved drugs, validated targets and mechanism-of-action data to potential new indications. NovaLead's lead asset, Galnobax® (a topical gel containing a repurposed generic for hard-to-heal Diabetic Foot Ulcer), completed a 350-patient Phase 3 trial in India, received CDSCO market authorization in April 2024, and is being commercialized in India as Diulcus® through a licensing deal with Ipca Laboratories announced in August 2024. A second program, NLP91, targets mild-to-moderate psoriasis and dermatitis and has a granted US patent covering broad inflammatory skin indications, with preclinical validation in progress.

The company's commercial model is asset-light and B2B: NovaLead performs discovery in-house, outsources biological validation, takes candidates through first human proof of concept, and then out-licenses to established pharmaceutical partners for marketing, sales and distribution. Revenue mechanics are licensing fees, milestone payments and royalties on partnered products, supplemented by optional customer-driven collaboration services where partners engage NovaLead's RVHTS platform to find new indications for their own molecules. The business operates across two legal entities — NovaLead Pharma Pvt. Ltd. (India headquarters and research base) and the wholly owned NovaLead Pharma Inc. (Shrewsbury, Massachusetts), which manages US clinical trials, patent filings and North American collaborations. NovaLead is privately held and venture-backed, with Tata Capital Healthcare Fund among disclosed investors and the founder (Supreet Deshpande, Managing Director) joined by CTO/co-founder Atul Aslekar and VP of Discovery Dr. Sudhir Kulkarni.

Short descriptiontext

NovaLead Pharma is a Pune-based drug discovery company that uses its proprietary RVHTS platform to find new therapeutic indications for generic drugs, with lead asset Galnobax® approved in India for Diabetic Foot Ulcer and out-licensed to Ipca Laboratories as Diulcus®.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPune, India
HQ citystring
Pune
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug repurposing research, computational drug discovery, virtual high throughput screening, diabetic foot ulcer therapy, pharmaceutical out-licensing
Industry2 codes
PRIMARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Drug Discovery Research and Pharmaceutical Repurposing
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Out-licensing and Partnership Deals
TypeLicensing Royalties
Description

NovaLead out-licenses its proprietary drug candidates to pharmaceutical partners after achieving first human proof of concept. Revenue is generated through licensing fees, milestone payments, and royalty streams from commercialization partners.

novaleadpharma.com
2Collaborative Research Services
TypeProfessional Services
Description

Customer-driven collaboration services where NovaLead helps partners find novel indications for existing drugs using their proprietary RVHTS discovery platform.

novaleadpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Galnobax®
Description

Topical gel for non-healing chronic wounds in diabetics; repurposed generic drug molecule that completed Phase III clinical trial successfully meeting primary and secondary endpoints for DFU treatment; received CDSCO market authorization in India

novaleadpharma.com
+2 more records
Core offering1 text field

NovaLead Pharma discovers new therapeutic indications for generic drugs using its proprietary Reverse Virtual High Throughput Screening (RVHTS) computational platform. Its lead product, Galnobax®, is a topical gel for non-healing Diabetic Foot Ulcer that received CDSCO market authorization in India and is licensed to Ipca Laboratories under the brand Diulcus®. Secondary candidate NLP91 is a US-patent-granted psoriasis treatment based on a repurposed FDA-approved generic molecule.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

NovaLead Pharma is a drug discovery research company focused on discovering new indications for generic drugs using its proprietary RVHTS (Reverse Virtual High Throughput Screening) technology platform. The company operates two main product candidates: Galnobax® (a topical gel for Diabetic Foot Ulcer) and NLP91 (a psoriasis candidate). The company also out-licenses its discoveries after first human proof of concept, as exemplified by the Diulcus® licensing to Ipca Laboratories. The discovery pipeline is managed through NovaLead Pharma Inc., a wholly owned US subsidiary.

Product and service4 records
1Galnobax®
CategoryRepurposed pharmaceutical product
Description

A topical gel for non-healing chronic wounds of diabetics, specifically for Diabetic Foot Ulcer (DFU). Repurposed generic drug molecule that re-triggers natural wound healing processes impaired due to diabetic condition. Completed Phase-III clinical trial successfully meeting both primary and secondary endpoints for wound closure and safety.

2NLP91
CategoryRepurposed pharmaceutical product
Description

Psoriasis candidate based on an FDA-approved generic drug molecule with novel anti-inflammatory activity for inflammatory skin diseases like psoriasis and dermatitis. Discovered using in-silico RVHTS technologies and validated by in vitro studies. Currently under pre-clinical validations in animal models.

3Diulcus®
CategoryOut-licensed pharmaceutical brand
Description

Licensed repurposed drug marketed by Ipca Laboratories in India for treatment of Diabetic Foot Ulcer (DFU). Launched as a pivotal treatment option for DFU patients in the Indian market.

4RVHTS Technology Platform
CategoryDrug discovery technology platform
Description

Reverse Virtual High Throughput Screening platform that blends structure-guided and ligand-based drug design and screening approaches. Includes flexible receptor-drug docking, molecular shape similarity identification, fragment-to-activity relationship studies, and active site structure analysis. Employs drug-disease-target knowledgebase and multi-core parallel processing for molecular simulations. Offered for product life-cycle management, reviving shelved compounds, and customer-driven indication discovery.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-08-16
Description

NovaLead licensed its patented repurposed drug Galnobax® (marketed as Diulcus®) to Ipca Laboratories for marketing, sales and distribution in India market. The launch of Diulcus® marks a pivotal moment for people suffering from Diabetic Foot Ulcer (DFU). NovaLead is actively exploring out-licensing the product in other territories.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Pharnext
TypeDirect peer
Description

Pharnext is a French clinical-stage biopharmaceutical company specializing in drug repurposing, applying combinations of existing drugs to new indications such as Charcot-Marie-Tooth disease. Comparable to NovaLead in its core strategy of repositioning known molecules for new therapeutic uses.

2Biovista
TypeDirect peer
Description

Biovista is a drug repositioning company that uses computational and AI-driven approaches to discover new indications for existing drugs, similar to NovaLead's RVHTS platform. Both companies monetize through partnerships and out-licensing of repurposed candidates.

TypeEmerging player
Description

Healx is an AI-driven drug repurposing company focused on rare diseases, leveraging computational prediction of drug-indication pairs. Comparable to NovaLead as a tech-enabled repurposing platform seeking to in-license and develop new indications for existing molecules.

TypeBroad incumbent
Description

Recursion is a clinical-stage biotech using high-throughput biology and AI to discover new drug candidates at scale. Like NovaLead, it applies computational and systematic approaches to accelerate discovery, though at significantly larger scale and broader therapeutic scope.

TypeBroad incumbent
Description

Insilico Medicine is a clinical-stage AI drug discovery company combining generative chemistry, target identification, and repurposing. Comparable to NovaLead in applying computational platforms to drug discovery, though operating at broader therapeutic scale and with proprietary novel chemistry.

TypeEmerging player
Description

Atomwise applies AI-based small molecule discovery and structure-based design through its AtomNet platform, partnering with pharma companies to identify novel hits and repurposing opportunities. Comparable as a technology-driven, partnership-focused discovery peer to NovaLead's RVHTS model.

TypeEmerging player
Description

Cyclica is a Toronto-based computational drug discovery company using AI and biophysics for polypharmacology and drug repurposing. Comparable to NovaLead as a computational platform that emphasizes drug-target interaction analysis and partnership-driven business model.

TypeBroad incumbent
Description

Organogenesis is a US-listed commercial-stage regenerative medicine company focused on advanced wound care including diabetic foot ulcers. Comparable to NovaLead in serving the DFU market, though with a portfolio of cell- and tissue-based products rather than topical repurposed drugs.

TypeOthers
Description

VLife Sciences Technologies is an Indian computational drug discovery company whose platform NovaLead explicitly references on its website as the related technology ecosystem. Founders have historical ties, making VLife a closely related platform peer.

10Connexios Life Sciences
TypeRegional player
Description

Connexios Life Sciences is an India-based drug discovery company developing small molecules for cardiometabolic and related diseases. Comparable as a regional, platform-driven drug discovery peer with similar therapeutic focus on diabetes-adjacent indications.

Market position
Competitive moat4 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NovaLead Pharma

Drug Discovery Research and Pharmaceutical Repurposingnovaleadpharma.com

NovaLead Pharma is a Pune-based drug discovery company that uses its proprietary RVHTS platform to find new therapeutic indications for generic drugs, with lead asset Galnobax® approved in India for Diabetic Foot Ulcer and out-licensed to Ipca Laboratories as Diulcus®.

What NovaLead Pharma does

NovaLead Pharma is a Pune, India-headquartered drug discovery research company that applies its proprietary Reverse Virtual High Throughput Screening (RVHTS) platform to repurpose already-approved generic drugs toward new therapeutic indications. The platform blends structure-guided and ligand-based drug design and screening, runs millions of molecular simulations on a multi-core parallel processing cluster, and is supported by a curated drug-disease-target knowledgebase that maps FDA-approved drugs, validated targets and mechanism-of-action data to potential new indications. NovaLead's lead asset, Galnobax® (a topical gel containing a repurposed generic for hard-to-heal Diabetic Foot Ulcer), completed a 350-patient Phase 3 trial in India, received CDSCO market authorization in April 2024, and is being commercialized in India as Diulcus® through a licensing deal with Ipca Laboratories announced in August 2024. A second program, NLP91, targets mild-to-moderate psoriasis and dermatitis and has a granted US patent covering broad inflammatory skin indications, with preclinical validation in progress.

The company's commercial model is asset-light and B2B: NovaLead performs discovery in-house, outsources biological validation, takes candidates through first human proof of concept, and then out-licenses to established pharmaceutical partners for marketing, sales and distribution. Revenue mechanics are licensing fees, milestone payments and royalties on partnered products, supplemented by optional customer-driven collaboration services where partners engage NovaLead's RVHTS platform to find new indications for their own molecules. The business operates across two legal entities — NovaLead Pharma Pvt. Ltd. (India headquarters and research base) and the wholly owned NovaLead Pharma Inc. (Shrewsbury, Massachusetts), which manages US clinical trials, patent filings and North American collaborations. NovaLead is privately held and venture-backed, with Tata Capital Healthcare Fund among disclosed investors and the founder (Supreet Deshpande, Managing Director) joined by CTO/co-founder Atul Aslekar and VP of Discovery Dr. Sudhir Kulkarni.

NovaLead Pharma firmographics

Firmographics
Name
NovaLead Pharma
Legal name
NovaLead Pharma Pvt. Ltd.
Website
https://novaleadpharma.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
NovaLead Pharma is a Pune-based drug discovery company that uses its proprietary RVHTS platform to find new therapeutic indications for generic drugs, with lead asset Galnobax® approved in India for Diabetic Foot Ulcer and out-licensed to Ipca Laboratories as Diulcus®.
Ownership category
akta.pro rank

NovaLead Pharma industry classification

Industry
Product category
Drug Discovery Research and Pharmaceutical Repurposing
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)

Keywords

  • Drug repurposing research
  • Computational drug discovery
  • Virtual high throughput screening
  • Diabetic foot ulcer therapy
  • Pharmaceutical out-licensing

Where NovaLead Pharma is headquartered

Location

Headquarters

HQ city
Pune
HQ country
India
HQ region
Asia

Offices2 records

Markets served

NovaLead Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Out-licensing and Partnership Deals: NovaLead out-licenses its proprietary drug candidates to pharmaceutical partners after achieving first human proof of concept. Revenue is generated through licensing fees, milestone payments, and royalty streams from commercialization partners.
  2. Collaborative Research Services: Customer-driven collaboration services where NovaLead helps partners find novel indications for existing drugs using their proprietary RVHTS discovery platform.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

NovaLead Pharma product offering

Product offering

Core offering

NovaLead Pharma discovers new therapeutic indications for generic drugs using its proprietary Reverse Virtual High Throughput Screening (RVHTS) computational platform. Its lead product, Galnobax®, is a topical gel for non-healing Diabetic Foot Ulcer that received CDSCO market authorization in India and is licensed to Ipca Laboratories under the brand Diulcus®. Secondary candidate NLP91 is a US-patent-granted psoriasis treatment based on a repurposed FDA-approved generic molecule.

Product overview

NovaLead Pharma is a drug discovery research company focused on discovering new indications for generic drugs using its proprietary RVHTS (Reverse Virtual High Throughput Screening) technology platform. The company operates two main product candidates: Galnobax® (a topical gel for Diabetic Foot Ulcer) and NLP91 (a psoriasis candidate). The company also out-licenses its discoveries after first human proof of concept, as exemplified by the Diulcus® licensing to Ipca Laboratories. The discovery pipeline is managed through NovaLead Pharma Inc., a wholly owned US subsidiary.

Differentiator

Problem solved

Functional benefit

Brands

  • Galnobax®: Topical gel for non-healing chronic wounds in diabetics; repurposed generic drug molecule that completed Phase III clinical trial successfully meeting primary and secondary endpoints for DFU treatment; received CDSCO market authorization in India
  • NLP91
  • Diulcus®

Products and services

  • Galnobax® A topical gel for non-healing chronic wounds of diabetics, specifically for Diabetic Foot Ulcer (DFU). Repurposed generic drug molecule that re-triggers natural wound healing processes impaired due to diabetic condition. Completed Phase-III clinical trial successfully meeting both primary and secondary endpoints for wound closure and safety.
  • NLP91 Psoriasis candidate based on an FDA-approved generic drug molecule with novel anti-inflammatory activity for inflammatory skin diseases like psoriasis and dermatitis. Discovered using in-silico RVHTS technologies and validated by in vitro studies. Currently under pre-clinical validations in animal models.
  • Diulcus® Licensed repurposed drug marketed by Ipca Laboratories in India for treatment of Diabetic Foot Ulcer (DFU). Launched as a pivotal treatment option for DFU patients in the Indian market.
  • RVHTS Technology Platform Reverse Virtual High Throughput Screening platform that blends structure-guided and ligand-based drug design and screening approaches. Includes flexible receptor-drug docking, molecular shape similarity identification, fragment-to-activity relationship studies, and active site structure analysis. Employs drug-disease-target knowledgebase and multi-core parallel processing for molecular simulations. Offered for product life-cycle management, reviving shelved compounds, and customer-driven indication discovery.

Companies that use NovaLead Pharma

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

NovaLead Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

NovaLead Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ipca LaboratoriesflagshipChannel Partner/ Reseller/ Distributor · 16 August 2024NovaLead licensed its patented repurposed drug Galnobax® (marketed as Diulcus®) to Ipca Laboratories for marketing, sales and distribution in India market. The launch of Diulcus® marks a pivotal moment for people suffering from Diabetic Foot Ulcer (DFU). NovaLead is actively exploring out-licensing the product in other territories.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

NovaLead Pharma competitors and assessment

Company assessment

Direct peers

  • Pharnext: Pharnext is a French clinical-stage biopharmaceutical company specializing in drug repurposing, applying combinations of existing drugs to new indications such as Charcot-Marie-Tooth disease. Comparable to NovaLead in its core strategy of repositioning known molecules for new therapeutic uses.
  • Biovista: Biovista is a drug repositioning company that uses computational and AI-driven approaches to discover new indications for existing drugs, similar to NovaLead's RVHTS platform. Both companies monetize through partnerships and out-licensing of repurposed candidates.

Emerging players

  • Healx: Healx is an AI-driven drug repurposing company focused on rare diseases, leveraging computational prediction of drug-indication pairs. Comparable to NovaLead as a tech-enabled repurposing platform seeking to in-license and develop new indications for existing molecules.
  • Atomwise: Atomwise applies AI-based small molecule discovery and structure-based design through its AtomNet platform, partnering with pharma companies to identify novel hits and repurposing opportunities. Comparable as a technology-driven, partnership-focused discovery peer to NovaLead's RVHTS model.
  • Cyclica: Cyclica is a Toronto-based computational drug discovery company using AI and biophysics for polypharmacology and drug repurposing. Comparable to NovaLead as a computational platform that emphasizes drug-target interaction analysis and partnership-driven business model.

Broad incumbents

  • Recursion Pharmaceuticals: Recursion is a clinical-stage biotech using high-throughput biology and AI to discover new drug candidates at scale. Like NovaLead, it applies computational and systematic approaches to accelerate discovery, though at significantly larger scale and broader therapeutic scope.
  • Insilico Medicine: Insilico Medicine is a clinical-stage AI drug discovery company combining generative chemistry, target identification, and repurposing. Comparable to NovaLead in applying computational platforms to drug discovery, though operating at broader therapeutic scale and with proprietary novel chemistry.
  • Organogenesis: Organogenesis is a US-listed commercial-stage regenerative medicine company focused on advanced wound care including diabetic foot ulcers. Comparable to NovaLead in serving the DFU market, though with a portfolio of cell- and tissue-based products rather than topical repurposed drugs.

Others

  • VLife Sciences Technologies: VLife Sciences Technologies is an Indian computational drug discovery company whose platform NovaLead explicitly references on its website as the related technology ecosystem. Founders have historical ties, making VLife a closely related platform peer.

Regional players

  • Connexios Life Sciences: Connexios Life Sciences is an India-based drug discovery company developing small molecules for cardiometabolic and related diseases. Comparable as a regional, platform-driven drug discovery peer with similar therapeutic focus on diabetes-adjacent indications.

Market position

Competitive moat4 records

Key highlights7 records

Customer concentration

NovaLead Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NovaLead Pharma leadership team

Management profile

Number of profiles

Profiles3 records

NovaLead Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

NovaLead Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NovaLead Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NovaLead Pharma

What does NovaLead Pharma do?

NovaLead Pharma discovers new therapeutic indications for generic drugs using its proprietary Reverse Virtual High Throughput Screening (RVHTS) computational platform. Its lead product, Galnobax®, is a topical gel for non-healing Diabetic Foot Ulcer that received CDSCO market authorization in India and is licensed to Ipca Laboratories under the brand Diulcus®. Secondary candidate NLP91 is a US-patent-granted psoriasis treatment based on a repurposed FDA-approved generic molecule.

Is NovaLead Pharma a public or private company?

NovaLead Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was NovaLead Pharma founded?

NovaLead Pharma was founded in -1. It employs 1 to 10 people.

Where is NovaLead Pharma based?

NovaLead Pharma is headquartered in Pune, India, in the Asia region.

How does NovaLead Pharma make money?

Two revenue lines are on record. Out-licensing and Partnership Deals are the primary driver. The others are collaborative Research Services.

Who are NovaLead Pharma's main competitors?

Direct peers on record are Pharnext and Biovista. Emerging players are Healx, Atomwise and Cyclica. Broad incumbents are Recursion Pharmaceuticals, Insilico Medicine and Organogenesis. VLife Sciences Technologies is listed as an others. Connexios Life Sciences is listed as a regional player.

Does NovaLead Pharma have an API?

No public API is recorded for NovaLead Pharma.

What industry is NovaLead Pharma in?

NovaLead Pharma's product category is Drug Discovery Research and Pharmaceutical Repurposing. Its primary akta.pro industry code is HLAIALAB, Lead Optimization & Preclinical Candidate Selection, with a secondary code of HLAIABAA, Small-Molecule Generics (Branded/Unbranded). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales